9 research outputs found
Adiponectina iria determinar o predomĂnio de VLDL alteradas na sĂndrome metabĂłlica
El objetivo del trabajo fue evaluar si la reducciĂłn de adiponectina (ADP) en el sĂndrome metabĂłlico (SMet), influencia las caracterĂsticas aterogĂ©nicas de VLDL. Se estudiaron 45 pacientes con SMet y 15 controles sanos. En suero en ayunas se midiĂł perfil lipĂdico, ácidos grasos libres (AGL), ADP, se aislĂł VLDL (d<1,006 g/L) caracterizándola en su composiciĂłn quĂmica y tamaño (HPLC-exclusiĂłn molecular). En plasma post-heparĂnico se determinĂł la actividad de lipoproteĂna lipasa (LPL). En SMet VLDL mostrĂł incremento de masa, nĂşmero de partĂculas, contenido en triglicĂ©ridos-VLDL y mayor proporciĂłn de VLDL grandes (p<0,05). El incremento de AGL correlacionĂł con la masa de VLDL (r=0,36; p=0,009), nĂşmero de partĂculas-VLDL (r=0,45; p=0,0006) y %-VLDL grandes (r=0,32; p=0,02). SMet mostrĂł descenso en ADP (7,4±4,8 vs.15,5±7,2 ÎĽg/mL, p=0,01) y en actividad de LPL (p=0,01), que correlacionaron entre si (r=0,38; p=0,01; ajustado por HOMA-IR y cintura: β=0,35; p=0,02).ADP correlacionĂł negativamente con AGL y %-VLDL grandes (p<0,03). Se concluye que en SMet la disminuciĂłn de ADP favorecerĂa la secreciĂłn de VLDL sobre-enriquecidas en triglicĂ©ridos y de mayor tamaño, y además retardarĂa el catabolismo de VLDL mediado por LPL, resultando en la acumulaciĂłn de VLDL alteradas en circulaciĂłn con caracterĂsticas aterogĂ©nicas.The aim of the work was to evaluate whether the reduction of adiponectin (ADP) in metabolic syndrome (MetS) affects the atherogenic features of VLDL. A total of 45 patients with MetS (ATPIII) and 15 healthy controls were studied. In fasting serum, lipid profile, free fatty acids (FFA) and ADP were determined. VLDL was isolated (d<1.006 g/L) and characterized in chemical composition and size (size exclusion-HPLC). In post-heparin plasma, lipoprotein lipase (LPL) activity was measured. In MetS, VLDL showed increased total mass, particle number, VLDL-triglyceride content and higher large-VLDL proportion (p<0.05). The increase in FFA correlated with VLDL mass (r=0.36; p=0.009), VLDL particle number (r=0.45; p=0.0006) and large-VLDL proportion (r=0.32; p=0.02). MetS patients showed a decrease in ADP (7.4±4.8 vs. 15.5±7.2 ÎĽg/mL, p=0.01) and in LPL activity (p=0.01), that positively correlated between them (r=0.38; p=0.01; adjusted by HOMA-IR and waist: β=0.35; p=0.02). ADP inversely correlated with FFA and large-VLDL% (p<0.03). It can be concluded that in MetS, decreased ADP would favour the secretion of triglyceride over-enriched and larger VLDL particles, and also would delay VLDL catabolism mediated by LPL, resulting in the accumulation of altered VLDL with atherogenic characteristics.O objetivo do trabalho foi avaliar se a redução da adiponectina (ADP) na sĂndrome metabĂłlica (SM), afeta as caracterĂsticas aterogĂŞnicas das VLDL. Foram estudados 45 indivĂduos com SM e 15 controles saudáveis. Em jejum, foi medido em soro o perfil lipĂdico, ácidos graxos livres (AGL) e ADP. Foram isoladas as VLDL (d <1,006 g / L) caracterizando-as em relação a sua composição quĂmica e tamanho (HPLC- exclusĂŁo molecular). No plasma pĂłs-heparina foi medida a atividade da lipoproteĂna lipase (LPL). Em indivĂduos com SM, as VLDL apresentaram aumento de massa, nĂşmero de partĂculas, conteĂşdo de triglicerĂdeos -VLDL e maior proporção de VLDL grandes (p<0,05). O aumento de AGL correlacionou com a massa de VLDL (r=0,36; p=0,009), nĂşmero de partĂculas -VLDL (r=0,45; p=0,0006) e percentual -VLDL grandes (r=0,32; p=0,02). A SM mostrou uma diminuição em ADP (7,4±4,8 vs. 15,5±7,2 ÎĽg/mL, p=0,01) e em atividade de LPL (p=0,01), que correlacionaram entre eles (r=0,38; p=0,01; ajustada por HOMA-IR e cintura: β=0,35; p=0,02). A ADP correlacionou em forma negativa com AGL e %-VLDL grandes (p<0,03). A conclusĂŁo Ă© que em indivĂduos com SM, a diminuição da ADP iria favorecer a secreção de VLDL super-enriquecidas em triglicerĂdeos e de maior tamanho, e tambĂ©m atrasaria o catabolismo das VLDL mediado por LPL, resultando na acumulação de VLDL alteradas em circulação com caracterĂsticas aterogĂŞnicas.Fil: Lucero, Diego MartĂn. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Miksztowicz, VerĂłnica Julieta. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: CacciagiĂş, Leonardo D.. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Lopez, Graciela Ines. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Fernandez Machulsky, Nahuel Hernan. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Zago, Valeria. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Schreier, Laura Ester. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentin
Remnant cholesterol levels are associated with severity and death in COVID-19 patients
Coronavirus disease-19 (COVID-19) patients with severe complications present comorbidities like cardiovascular-disease, hypertension and type-2 diabetes mellitus (DM), sharing metabolic alterations like insulin resistance (IR) and dyslipidemia. Our objective was to evaluate the association among different components of the lipid-lipoprotein profile, such as remnant lipoprotein (RLP)-cholesterol, in patients with COVID-19, and to analyze their associations with the severity of the disease and death. We studied 193 patients (68 (29–96) years; 49.7% male) hospitalized for COVID-19 and 200 controls (46 (18–79) years; 52.5% male). Lipoprotein profile, glucose and procalcitonin were assessed. Patients presented higher glucose, TG, TG/HDL-cholesterol and RLP-cholesterol levels, but lower total, LDL, HDL and no-HDL-cholesterol levels (p < 0.001). When a binary logistic regression was performed, age, non-HDL-cholesterol, and RLP-cholesterol were associated with death (p = 0.005). As the COVID-19 condition worsened, according to procalcitonin tertiles, a decrease in all the cholesterol fractions (p < 0.03) was observed with no differences in TG, while levels of RLP-cholesterol and TG/HDL-cholesterol increased (p < 0.001). Lower levels of all the cholesterol fractions were related with the presence and severity of COVID-19, except for RLP-cholesterol levels and TG/HDL-cholesterol index. These alterations indicate a lipid metabolic disorder, characteristic of IR states in COVID-19 patients. RLP-cholesterol levels predicted severity and death in these patients.Fil: Fabre, Bibiana. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; ArgentinaFil: Fernandez Machulsky, Nahuel Hernan. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; ArgentinaFil: Olano, Carolina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; ArgentinaFil: Jacobsen, DarĂo. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Gomez, Maria Eugenia. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Perazzi, Beatriz Elizabeth. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay; ArgentinaFil: Zago, Valeria. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; ArgentinaFil: Zopatti, Damián. Universidad de Buenos Aires. Facultad de Medicina. Hospital de ClĂnicas General San MartĂn; ArgentinaFil: Ferrero, AndrĂ©s. Universidad de Buenos Aires. Facultad de Medicina. Hospital de ClĂnicas General San MartĂn; ArgentinaFil: Schreier, Laura Ester. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; ArgentinaFil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; Argentin
Hair Cortisol Measurement by an Automated Method
We present the development of the first procedure for hair cortisol measurement through an automated method. Hair samples were obtained from 286 individuals. After cortisol extraction, samples were measured in a Siemens Immulite 2000 (Gwynedd, UK) automated chemoluminiscent immunoassay analyzer. Normal reference values were obtained from hair cortisol levels measured in 213 healthy individuals with low levels of stress. Hair cortisol concentration median was 55 pg/mg hair (2.5–97.5 percentile (40–128)) in healthy individuals with low levels of stress and 250 pg/mg hair (range 182–520) in stressed individuals. No significant differences were observed in hair cortisol levels between subjects with and without dye (40 (40–107) and 40 (40–155) pg/mg hair, respectively; p = 0.128). The novel procedure presented here shows an adequate analytical performance.Fil: Gonzalez, Diego Javier. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; ArgentinaFil: Jacobsen, Dario Gustavo. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Ibar, Carolina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Pavan, Carlos Humberto. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay. Instituto de QuĂmica y FĂsico-QuĂmica BiolĂłgicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de QuĂmica y FĂsico-QuĂmica BiolĂłgicas; ArgentinaFil: Monti, JosĂ© Luis Eugenio. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay. Instituto de QuĂmica y FĂsico-QuĂmica BiolĂłgicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de QuĂmica y FĂsico-QuĂmica BiolĂłgicas; ArgentinaFil: Fernandez Machulsky, Nahuel Hernan. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; ArgentinaFil: Balbi, Ayelen. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Fritzler, Melisa Araceli. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Jamardo, Juan. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Repetto, Esteban M.. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Berg, Gabriela Alicia. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay; ArgentinaFil: Fabre, Bibiana. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; Argentin
Matrix metalloproteinases and psychosocial factors in acute coronary syndrome patients
Psychosocial factors have been linked to cardiovascular diseases independently of traditional risk factors. The impact of psychosocial factors on plaque destabilizing factors, such as matrix metalloproteinases (MMPs) has been proposed although scarcely studied. Objective: To evaluate the relationships between hostility, perceived stress and social support with MMPs activity in patients after an Acute Myocardial Infarction (AMI). Methods: Blood samples were obtained from 76 patients on admission, post-angioplasty, 24. h, 7 days and 3 months after AMI. Hostility, perceived stress and social support were evaluated by validated questionnaires. Results: Social support was positively correlated with patientĹ› ejection fraction (r = 0.453, p = 0.009). Patients with higher infarct size presented increased MMP-2 activity at admission (p = 0.04). Patients with one diseased vessel had more social support than those with three diseased vessels (p = 0.05). The highest values of MMP-2 and MMP-9 activity were observed at the acute event, decreasing, with the lowest activity at 3 months post-AMI (p < 0.001). Only in patients with low social support, hostility correlated with MMP-2 activity, from AMI onset (r = 0.645, p = 0.013), to 7 days post AMI (r = 0.557, p = 0.038). Hostility explained up to 28% of the variance in MMP-2 activity (R2=0.28, p = 0.005). Finally, in patients with high hostility, MMP-9 was positively correlated with IL-1β (r = 0.468, p = 0.02). Conclusions: This study adds weight to the idea that two psychosocial factors, namely hostility and social support, acting jointly, may affect MMP-2 activity. Moreover, in hostile patients, there is a link between IL-1β and MMP-9. These findings support the role of psychosocial factors in plaque destabilization and in the inflammatory process in AMI.Fil: Fernandez Machulsky, Nahuel Hernan. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Ministerio de Defensa. EjĂ©rcito Argentino. Hospital Militar Central Cirujano Mayor "Dr. Cosme Argerich"; ArgentinaFil: Fabre, Bibiana. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Miksztowicz, VerĂłnica Julieta. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Lombardo, Micaela. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: GarcĂa Escudero, Alejandro. Ministerio de Defensa. EjĂ©rcito Argentino. Hospital Militar Central Cirujano Mayor "Dr. Cosme Argerich"; ArgentinaFil: Gigena, Gerardo. Ministerio de Defensa. EjĂ©rcito Argentino. Hospital Militar Central Cirujano Mayor "Dr. Cosme Argerich"; ArgentinaFil: Blanco, Federico Carlos. Ministerio de Defensa. EjĂ©rcito Argentino. Hospital Militar Central Cirujano Mayor "Dr. Cosme Argerich"; ArgentinaFil: Gelpi, Ricardo Jorge. Universidad de Buenos Aires. Facultad de Medicina. Instituto de FisiopatologĂa Cardiovascular; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Schreier, Laura Ester. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Gidron, Yori. Vrije Unviversiteit Brussel; BĂ©lgicaFil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentin
Increase in MMP-2 activity in overweight and obese women is associated with menopausal status
Background Metalloproteinases (MMPs) are synthesized in the subendothelium and are involved in the atherosclerosis and cardiovascular disease process because of their major significance in vascular remodeling and plaque rupture. MMPs are also synthesized in adipose tissue during angiogenesis; however, the role of these enzymes in obesity and insulin-resistant states is still controversial. Objective To evaluate MMP-2 activity in the circulation of overweight and obese women and in normal-weight controls, and to associate the levels of these factors with metabolic, adipose tissue and inflammation biomarkers. Methods Plasma MMP-2 activity, adiponectin and C-reactive protein concentration, lipoprotein profile and HOMA were determined in 39 healthy women (13 normal weight and 26 overweight/obese). Results Overweight/obese women were older (p <0.001) than normal-weight women; 20/26 of overweight/obese women were postmenopausal compared with 4/13 of normal-weight women. Overweight/obese women had significantly higher plasma activity of MMP-2 than controls (mean relative area: 0.81 (range 0.4-1.92) vs. 1.33 (range 0.4-3.1); p <0.005); this difference was lost after adjusting for menopausal status. MMP-2 activity positively correlated with waist circumference (p <0.002), HOMA (p <0.003), and high-sensitivity C-reactive protein (p <0.05), apolipoprotein B (p =0.006) and triglyceride/high density lipoprotein (HDL) cholesterol index (p <0.001), and negatively with HDL cholesterol (p <0.001), HDL2 cholesterol (p <0.008), HDL3 cholesterol (p <0.05) and adiponectin (p <0.05). The association with HOMA and adiponectin persisted even after adjusting for menopausal status. Conclusion Our finding of increased plasma activity of MMP-2 in overweight/obese women, associated with menopausal status, is important given that it fits in with an early stage of cardiovascular disease; the association of MMP-2 activity with obesity markers may be a link between adipose tissue and risk for cardiovascular disease.Fil: Miksztowicz, VerĂłnica Julieta. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay; ArgentinaFil: Siseles, Nestor O.. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay; ArgentinaFil: Fernandez Machulsky, Nahuel Hernan. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Schreier, Laura Ester. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Berg, Gabriela Alicia. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay; Argentin
Dynamics of circulating lipoproteins and lipids in Brown Skua (Stercorarius antarcticus lonnbergi) during the breeding cycle
In central-place foragers the breeding cycle is often the period with the highest energy cost, where dietary and stored lipids play a key role. Lipids are mobilized through blood lipoproteins providing fuel to tissues. Thus, the use of food and endogenous resources with high-energy fats is important to sustain individuals’ nutritional demands. To evaluate the physiological components associated to energetic demands and their variation regarding life history processes, we analysed the plasma circulating lipoprotein levels, the lipid classes and fatty acid (FA) composition in Brown Skua (Stercorarius antarcticus lonnbergi) in breeding stages with different energy requirements: incubation (In), early rearing (Er) and late rearing (Lr). We expected to find differences according to the energy demands of each stage and the sex. The level of Very Low Density lipoproteins was affected by the sex and the breeding stage, whereas Low Density lipoproteins only by the stage. Total plasma lipid content and circulating lipid classes were invariant among the stages studied; however, differences in total plasma FA and monounsaturated FA (oleic and nervonic) abundances were observed among stages. Besides, a decrease in the n-3:n-6 ratio was observed towards the Lr stage. The differences found in lipoproteins may be linked to changes in the energy demands throughout the breeding period. Moreover, the variation observed in FA abundance and n-3:n-6 ratio may be related to a preferential mobilization of FA from stores as fuel or, possibly, to a differential use of the available food resources.Fil: Ibañez, Andres Esteban. Universidad Nacional de La Plata. Facultad de Ciencias Naturales y Museo. DivisiĂłn ZoologĂa de Vertebrados. SecciĂłn OrnitologĂa; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - La Plata; ArgentinaFil: Pasquevich, MarĂa Yanina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - La Plata. Instituto de Investigaciones BioquĂmicas de La Plata "Prof. Dr. Rodolfo R. Brenner". Universidad Nacional de la Plata. Facultad de Ciencias MĂ©dicas. Instituto de Investigaciones BioquĂmicas de La Plata "Prof. Dr. Rodolfo R. Brenner"; ArgentinaFil: Fernandez Machulsky, Nahuel Hernan. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Berg, Gabriela Alicia. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Heras, Horacio. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - La Plata. Instituto de Investigaciones BioquĂmicas de La Plata "Prof. Dr. Rodolfo R. Brenner". Universidad Nacional de la Plata. Facultad de Ciencias MĂ©dicas. Instituto de Investigaciones BioquĂmicas de La Plata "Prof. Dr. Rodolfo R. Brenner"; ArgentinaFil: Montalti, Diego. Universidad Nacional de La Plata. Facultad de Ciencias Naturales y Museo. DivisiĂłn ZoologĂa de Vertebrados. SecciĂłn OrnitologĂa; Argentina. Ministerio de Relaciones Exteriores, Comercio Interno y Culto. DirecciĂłn Nacional del Antártico. Instituto Antártico Argentino; ArgentinaFil: Graña Grilli, Maricel. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - Patagonia Norte. Instituto de Investigaciones en Biodiversidad y Medioambiente. Universidad Nacional del Comahue. Centro Regional Universidad Bariloche. Instituto de Investigaciones en Biodiversidad y Medioambiente; Argentin
Vitamin D is related to markers of vulnerable plaque in acute myocardial infarction
Background: Vitamin D is a fat soluble vitamin involved in calcium and bone metabolism; recently its deficiency has been related to cardiovascular disease. In cardiac tissue, vitamin D suppresses metalloproteinases (MMPs) expression, enzymes directly associated with vulnerable plaque. Objective: To investigate whether the association between vitamin D and leptin is related to markers of vulnerable plaque, such as MMPs in patients with acute myocardial infarction. Methods: We studied 66 male patients with acute myocardial infarction, undergoing primary angioplasty. Blood samples were obtained at admission and 24hs after the surgery. Leptin and vitamin D concentrations in serum and MMP-2 and -9 activities in plasma were determined. Results: MMP-2 activity was increased in Vitamin D deficient/insufficient patients at admission (p=0.04) and 24 hs later (p=0.05). In a linear regression model, vitamin D explained 24% of the variance of MMP-2 activity (F=2.839 p=0.04). At admission, vitamin D correlated with serum leptin (r=-0.302 p=0.033), and explained 39.5% of its variation (F=4.432 p=0.003). Conclusions: In the studied population, vitamin D was inversely related to MMP-2 and leptin which are involved in coronary artery disease and acute myocardial infarction. The decrease in this hormone levels would be associated with a worse metabolic profile in acute coronary syndrome patients.Fil: Fernandez Machulsky, Nahuel Hernan. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; ArgentinaFil: Barchuk, MagalĂ. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; ArgentinaFil: Gagliardi, Juan Alberto. Gobierno de la Ciudad AutĂłnoma de Buenos Aires. Hospital General de Agudos Doctor Cosme Argerich; ArgentinaFil: Gonzalez, Diego Javier. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Lombardo, Micaela. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; ArgentinaFil: GarcĂa Escudero, Alejandro. Gobierno de la Ciudad AutĂłnoma de Buenos Aires. Hospital General de Agudos Doctor Cosme Argerich; ArgentinaFil: Gigena, Gerardo. Gobierno de la Ciudad AutĂłnoma de Buenos Aires. Hospital General de Agudos Doctor Cosme Argerich; ArgentinaFil: Blanco, Federico. Gobierno de la Ciudad AutĂłnoma de Buenos Aires. Hospital General de Agudos Doctor Cosme Argerich; ArgentinaFil: Schreier, Laura Ester. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Fabre, Bibiana. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Berg, Gabriela Alicia. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; Argentin
Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability
The aim of the study was to compare the effects of chronic oral treatment with carvedilol or amlodipine on blood pressure, blood pressure variability and target organ damage in N-nitro-l-arginine methyl ester (L-NAME) hypertensive rats. Wistar rats were treated with L-NAME administered in the drinking water for 8 weeks together with oral administration of carvedilol 30 mg/kg (n = 6), amlodipine 10 mg/kg (n = 6), or vehicle (n = 6). At the end of the treatment, echocardiographic evaluation, blood pressure, and short-term variability measurements were performed. Left ventricular and thoracic aortas were removed to assess activity of metalloproteinase 2 and 9 and expression levels of transforming growth factor β, tumor necrosis factor α, and interleukin 6. Histological samples were prepared from both tissues. Carvedilol and amlodipine induced a comparable reduction of systolic and mean arterial pressure and its short-term variability in L-NAME rats. The expression of transforming growth factor β, tumor necrosis factor α, and interleukin 6 decreased in both organs after carvedilol or amlodipine treatment and the activity of metalloproteinase was reduced in aortic tissue. Treatment with carvedilol or amlodipine completely prevented left ventricular collagen deposition and morphometric alterations in aorta. Oral chronic treatment with carvedilol or amlodipine significantly attenuates blood pressure variability and reduces target organ damage and biomarkers of tissue fibrosis and inflammation in L-NAME hypertensive rats.Fil: del Mauro, Julieta SofĂa. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica; ArgentinaFil: Prince, Paula Denise. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay. Instituto de BioquĂmica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de BioquĂmica y Medicina Molecular; ArgentinaFil: Donato, Pablo MartĂn. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de FisiopatologĂa Cardiovascular; ArgentinaFil: Fernandez Machulsky, Nahuel Hernan. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica; ArgentinaFil: Moretton, Marcela AnalĂa. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de TecnologĂa FarmacĂ©utica; ArgentinaFil: González, Germán Esteban. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de FisiopatologĂa Cardiovascular; ArgentinaFil: Bertera, Facundo Martin. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica; ArgentinaFil: Carranza, Maria Andrea. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica; ArgentinaFil: Gorzalczany, Susana Beatriz. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica; ArgentinaFil: Chiappetta, Diego AndrĂ©s. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de TecnologĂa FarmacĂ©utica; ArgentinaFil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica; ArgentinaFil: Morales, Celina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de FisiopatologĂa Cardiovascular; ArgentinaFil: Gelpi, Ricardo Jorge. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de FisiopatologĂa Cardiovascular; ArgentinaFil: Taira, Carlos Alberto. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica; ArgentinaFil: Höcht, Christian. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica; Argentin
Nebivolol is more effective than atenolol for blood pressure variability attenuation and target organ damage prevention in L-NAME hypertensive rats
β-Adrenergic blockers are no longer recommended as first-line therapy due to the reduced cardioprotection of traditional β-blockers compared with other antihypertensive drugs. It is unknown whether third-generation β-blockers share the limitations of traditional β-blockers. The aim of the present study was to compare the effects of nebivolol or atenolol on central and peripheral systolic blood pressure (SBP) and its variability and target organ damage (TOD) in N-nitro-L-arginine methyl ester (L-NAME) hypertensive rats. Male Wistar rats were treated with L-NAME for 8 weeks together with oral administration of nebivolol 30 mg/kg (n = 8), atenolol 90 mg/kg (n = 8), or vehicle (n = 8). The control group was composed of vehicle-treated Wistar rats. SBP and its variability, as well as echocardiographic parameters, were assessed during the last 2 weeks of treatment. Tissue levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and transforming growth factor β (TGF-β), and histopathological parameters were evaluated in the left ventricle and aorta. Nebivolol had a greater ability than atenolol to decrease central SBP and mid-term and short-term blood pressure variability (BPV) in L-NAME rats. Echocardiographic analysis showed that nebivolol was more effective than atenolol on E/A wave ratio normalization. Compared with atenolol treatment, nebivolol had a greater protective effect on different TOD markers, inducing a decrease in collagen deposition and a reduction in the proinflammatory cytokines IL-6 and TNF-α in the left ventricle and aorta. Our findings suggest that the adverse hemodynamic profile and the reduced cardiovascular protection reported with traditional β-blockers must not be carried forward to third-generation β-blockers.Fil: del Mauro, Julieta SofĂa. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de FarmacologĂa; ArgentinaFil: Prince, Paula Denise. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay. Instituto de BioquĂmica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de BioquĂmica y Medicina Molecular; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de QuĂmica AnalĂtica y FisicoquĂmica. Cátedra de FisicoquĂmica; ArgentinaFil: Santander Plantamura, Yanina Alejandra. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de FarmacologĂa; ArgentinaFil: Allo, Miguel Angel. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de FarmacologĂa; ArgentinaFil: Parola, Luciano. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de FarmacologĂa; ArgentinaFil: Fernandez Machulsky, Nahuel Hernan. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; ArgentinaFil: Moretton, Marcela AnalĂa. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de TecnologĂa FarmacĂ©utica; ArgentinaFil: Bin, Eliana Pamela. Universidad de Buenos Aires. Facultad de Medicina. Instituto de FisiopatologĂa Cardiovascular; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de PatologĂa; ArgentinaFil: González, Germán Esteban. Pontificia Universidad CatĂłlica Argentina "Santa MarĂa de los Buenos Aires". Instituto de Investigaciones BiomĂ©dicas. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay. Instituto de Investigaciones BiomĂ©dicas; ArgentinaFil: Bertera, Facundo Martin. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de FarmacologĂa; ArgentinaFil: Carranza, Maria Andrea. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de FarmacologĂa; ArgentinaFil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de BioquĂmica ClĂnica; ArgentinaFil: Taira, Carlos Alberto. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de FarmacologĂa; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; ArgentinaFil: Donato, Pablo MartĂn. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de FisiopatologĂa Cardiovascular; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de PatologĂa; ArgentinaFil: Chiappetta, Diego AndrĂ©s. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de TecnologĂa FarmacĂ©utica; ArgentinaFil: Polizio, Ariel HĂ©ctor. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de FarmacologĂa; ArgentinaFil: Höcht, Christian. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Departamento de FarmacologĂa; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquĂmica. Instituto de FisiopatologĂa y BioquĂmica ClĂnica; Argentin